On November 21, 2019 Immune-Onc Therapeutics, Inc. ("Immune-Onc") is a privately held cancer immunotherapy company reported to the discovery and development of novel biologic treatments for cancer patients (Press release, Immune-Onc Therapeutics, NOV 21, 2019, View Source [SID1234551587]). The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit www.immune-onc.com.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Company:
Immune-Onc Therapeutics, Inc.
Headquarters Address:
795 San Antonio Road
Palo Alto, CA 94303
Main Telephone:
16504571745
Website:
www.Immune-Onc.com
Type of Organization:
Private
Industry:
Biotechnology
Key Executives:
CEO: Charlene Liao
Public Relations
Contact:
Tara Cooper
Phone:
650-303-7306
Email: